Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Frameless Stereotactic Radiosurgery on the Gamma Knife Icon: Early Experience From 100 Patients.

Vulpe H, Save AV, Xu Y, Elliston CD, Garrett MD, Wu CC, Cheng SK, Jani AH, Bruce JN, McKhann GM, Wang TJC, Sisti MB.

Neurosurgery. 2019 Aug 2. pii: nyz227. doi: 10.1093/neuros/nyz227. [Epub ahead of print]

PMID:
31375826
2.

Monitoring Radiation Treatment Effects in Glioblastoma: FLAIR Volume as Significant Predictor of Survival.

Garrett MD, Yanagihara TK, Yeh R, McKhann GM, Sisti MB, Bruce JN, Sheth SA, Sonabend AM, Wang TJC.

Tomography. 2017 Sep;3(3):131-137. doi: 10.18383/j.tom.2017.00009.

3.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM.

Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.

4.

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.

Whittaker SR, Barlow C, Martin MP, Mancusi C, Wagner S, Self A, Barrie E, Te Poele R, Sharp S, Brown N, Wilson S, Jackson W, Fischer PM, Clarke PA, Walton MI, McDonald E, Blagg J, Noble M, Garrett MD, Workman P.

Mol Oncol. 2018 Mar;12(3):287-304. doi: 10.1002/1878-0261.12148. Epub 2018 Jan 28.

5.

Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.

Saintas E, Abrahams L, Ahmad GT, Ajakaiye AM, AlHumaidi AS, Ashmore-Harris C, Clark I, Dura UK, Fixmer CN, Ike-Morris C, Mato Prado M, Mccullough D, Mishra S, Schöler KM, Timur H, Williamson MD, Alatsatianos M, Bahsoun B, Blackburn E, Hogwood CE, Lithgow PE, Rowe M, Yiangou L, Rothweiler F, Cinatl J Jr, Zehner R, Baines AJ, Garrett MD, Gourlay CW, Griffin DK, Gullick WJ, Hargreaves E, Howard MJ, Lloyd DR, Rossman JS, Smales CM, Tsaousis AD, von der Haar T, Wass MN, Michaelis M.

PLoS One. 2017 Feb 13;12(2):e0172140. doi: 10.1371/journal.pone.0172140. eCollection 2017.

6.

Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Prockop S, Sauter C, Tamari R, van den Brink MR, Avecilla ST, Meagher R, O'Reilly RJ, Goldberg JD, Young JW, Giralt S, Perales MA, Ponce DM.

Biol Blood Marrow Transplant. 2017 Mar;23(3):452-458. doi: 10.1016/j.bbmt.2016.12.633. Epub 2016 Dec 23.

7.

Expression of functional neuronal receptor latrophilin 1 in human acute myeloid leukaemia cells.

Sumbayev VV, Gonçalves Silva I, Blackburn J, Gibbs BF, Yasinska IM, Garrett MD, Tonevitsky AG, Ushkaryov YA.

Oncotarget. 2016 Jul 19;7(29):45575-45583. doi: 10.18632/oncotarget.10039.

8.

Radiation Therapy for the Management of Brain Metastases.

Garrett MD, Wu CC, Yanagihara TK, Jani A, Wang TJ.

Am J Clin Oncol. 2016 Aug;39(4):416-22. doi: 10.1097/COC.0000000000000296. Review.

PMID:
27213494
9.

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

Osborne JD, Matthews TP, McHardy T, Proisy N, Cheung KM, Lainchbury M, Brown N, Walton MI, Eve PD, Boxall KJ, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Jamin Y, Robinson SP, Westwood IM, van Montfort RL, Leonard PM, Lamers MB, Reader JC, Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I.

J Med Chem. 2016 Jun 9;59(11):5221-37. doi: 10.1021/acs.jmedchem.5b01938. Epub 2016 May 23.

10.

Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.

Wang TJC, Wu CC, Jani A, Estrada J, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb C, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, McKhann GM 2nd.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):306-314. doi: 10.1016/j.prro.2015.12.001. Epub 2015 Dec 4.

PMID:
26952813
11.

A Modern Radiotherapy Series of Survival in Hispanic Patients with Glioblastoma.

Wu CC, Wang TJ, Jani A, Estrada JP, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb CS, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, McKhann GM 2nd.

World Neurosurg. 2016 Apr;88:260-9. doi: 10.1016/j.wneu.2015.12.081. Epub 2015 Dec 31.

PMID:
26746331
12.

Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.

Smith JR, Moreno L, Heaton SP, Chesler L, Pearson AD, Garrett MD.

Mol Oncol. 2016 Apr;10(4):538-52. doi: 10.1016/j.molonc.2015.11.005. Epub 2015 Nov 19.

13.

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.

Walton MI, Eve PD, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Boxall KJ, Tall M, Swales K, Matthews TP, McHardy T, Lainchbury M, Osborne J, Hunter JE, Perkins ND, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Collins I, Garrett MD.

Oncotarget. 2016 Jan 19;7(3):2329-42. doi: 10.18632/oncotarget.4919.

14.

Mental health disorders among an invisible minority: depression and dementia among american Indian and alaska native elders.

Garrett MD, Baldridge D, Benson W, Crowder J, Aldrich N.

Gerontologist. 2015 Apr;55(2):227-36. doi: 10.1093/geront/gnu181. Epub 2015 Feb 15.

PMID:
26035598
15.

Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.

Sadok A, McCarthy A, Caldwell J, Collins I, Garrett MD, Yeo M, Hooper S, Sahai E, Kuemper S, Mardakheh FK, Marshall CJ.

Cancer Res. 2015 Jun 1;75(11):2272-84. doi: 10.1158/0008-5472.CAN-14-2156. Epub 2015 Apr 3.

16.

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.

Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos KP, Olmos D, Baird R, Delgado L, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW.

Clin Cancer Res. 2014 Nov 15;20(22):5672-85. doi: 10.1158/1078-0432.CCR-14-0868. Epub 2014 Sep 19.

17.

A methodological critique of the National Institute of Aging and Alzheimer's Association Guidelines for Alzheimer's disease, dementia, and mild cognitive impairments.

Garrett MD, Valle R.

Dementia (London). 2016 Mar;15(2):239-54. doi: 10.1177/1471301214525166. Epub 2014 Mar 24.

PMID:
24662500
18.

Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2.

Silva-Santisteban MC, Westwood IM, Boxall K, Brown N, Peacock S, McAndrew C, Barrie E, Richards M, Mirza A, Oliver AW, Burke R, Hoelder S, Jones K, Aherne GW, Blagg J, Collins I, Garrett MD, van Montfort RL.

PLoS One. 2013 Jun 12;8(6):e65689. doi: 10.1371/journal.pone.0065689. Print 2013.

19.

JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.

Walters ZS, Villarejo-Balcells B, Olmos D, Buist TW, Missiaglia E, Allen R, Al-Lazikani B, Garrett MD, Blagg J, Shipley J.

Oncogene. 2014 Feb 27;33(9):1148-57. doi: 10.1038/onc.2013.46. Epub 2013 Feb 25.

20.

Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.

Lainchbury M, Matthews TP, McHardy T, Boxall KJ, Walton MI, Eve PD, Hayes A, Valenti MR, de Haven Brandon AK, Box G, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Garrett MD, Collins I.

J Med Chem. 2012 Nov 26;55(22):10229-40. doi: 10.1021/jm3012933. Epub 2012 Oct 19.

21.

Targeted radiosensitization by the Chk1 inhibitor SAR-020106.

Borst GR, McLaughlin M, Kyula JN, Neijenhuis S, Khan A, Good J, Zaidi S, Powell NG, Meier P, Collins I, Garrett MD, Verheij M, Harrington KJ.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1110-8. doi: 10.1016/j.ijrobp.2012.08.006. Epub 2012 Sep 14.

PMID:
22981708
22.

CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.

Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, Hallsworth A, Smith EL, Boxall KJ, Lainchbury M, Matthews TP, Jamin Y, Robinson SP, Aherne GW, Reader JC, Chesler L, Raynaud FI, Eccles SA, Collins I, Garrett MD.

Clin Cancer Res. 2012 Oct 15;18(20):5650-61. doi: 10.1158/1078-0432.CCR-12-1322. Epub 2012 Aug 28.

23.

AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.

Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD.

Clin Cancer Res. 2012 Jul 15;18(14):3912-23. doi: 10.1158/1078-0432.CCR-11-3313. Epub 2012 Jul 10.

24.

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

Carden CP, Stewart A, Thavasu P, Kipps E, Pope L, Crespo M, Miranda S, Attard G, Garrett MD, Clarke PA, Workman P, de Bono JS, Gore M, Kaye SB, Banerji U.

Mol Cancer Ther. 2012 Jul;11(7):1609-17. doi: 10.1158/1535-7163.MCT-11-0996. Epub 2012 May 3.

25.

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.

Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall M, Stewart A, Raynaud F, Garrett MD, Toal M, Hooftman L, De Bono JS, Verweij J, Eskens FA.

Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.

26.

Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling.

Stockwell SR, Platt G, Barrie SE, Zoumpoulidou G, Te Poele RH, Aherne GW, Wilson SC, Sheldrake P, McDonald E, Venet M, Soudy C, Elustondo F, Rigoreau L, Blagg J, Workman P, Garrett MD, Mittnacht S.

PLoS One. 2012;7(1):e28568. doi: 10.1371/journal.pone.0028568. Epub 2012 Jan 12.

27.

Elder abuse and oral health care providers: an intervention to increase knowledge and self-perceived likelihood to report.

Sugita JA, Garrett MD.

J Elder Abuse Negl. 2012;24(1):50-64. doi: 10.1080/08946566.2011.608051.

PMID:
22206512
28.

Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.

Reader JC, Matthews TP, Klair S, Cheung KM, Scanlon J, Proisy N, Addison G, Ellard J, Piton N, Taylor S, Cherry M, Fisher M, Boxall K, Burns S, Walton MI, Westwood IM, Hayes A, Eve P, Valenti M, de Haven Brandon A, Box G, van Montfort RL, Williams DH, Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I.

J Med Chem. 2011 Dec 22;54(24):8328-42. doi: 10.1021/jm2007326. Epub 2011 Nov 23.

29.

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW.

J Clin Oncol. 2011 Dec 10;29(35):4688-95. doi: 10.1200/JCO.2011.35.5263. Epub 2011 Oct 24.

PMID:
22025163
30.

Anticancer therapy with checkpoint inhibitors: what, where and when?

Garrett MD, Collins I.

Trends Pharmacol Sci. 2011 May;32(5):308-16. doi: 10.1016/j.tips.2011.02.014. Epub 2011 Mar 30. Review.

PMID:
21458083
31.

Obesity and other cardiovascular disease risk factors and their association with osteoarthritis in Southern California American Indians, 2002-2006.

Reid JL, Morton DJ, Wingard DL, Garrett MD, von Muhlen D, Slymen D.

Ethn Dis. 2010 Autumn;20(4):416-22.

PMID:
21305831
32.

CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.

Anderson VE, Walton MI, Eve PD, Boxall KJ, Antoni L, Caldwell JJ, Aherne W, Pearl LH, Oliver AW, Collins I, Garrett MD.

Cancer Res. 2011 Jan 15;71(2):463-72. doi: 10.1158/0008-5472.CAN-10-1252.

33.

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

Yap TA, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD.

Mol Cancer Ther. 2011 Feb;10(2):360-71. doi: 10.1158/1535-7163.MCT-10-0760. Epub 2010 Dec 29.

34.

Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.

Caldwell JJ, Welsh EJ, Matijssen C, Anderson VE, Antoni L, Boxall K, Urban F, Hayes A, Raynaud FI, Rigoreau LJ, Raynham T, Aherne GW, Pearl LH, Oliver AW, Garrett MD, Collins I.

J Med Chem. 2011 Jan 27;54(2):580-90. doi: 10.1021/jm101150b. Epub 2010 Dec 27.

PMID:
21186793
35.

Sex and age differences in the association of obesity and smoking with hypertension and type 2 diabetes in Southern California American Indians, 2002-2006.

Reid JL, Morton DJ, Wingard DL, Garrett MD, von Muhlen D, Slymen D, Field M.

Ethn Dis. 2010 Summer;20(3):231-8.

PMID:
20828095
36.

Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases.

Matthews TP, McHardy T, Klair S, Boxall K, Fisher M, Cherry M, Allen CE, Addison GJ, Ellard J, Aherne GW, Westwood IM, van Montfort R, Garrett MD, Reader JC, Collins I.

Bioorg Med Chem Lett. 2010 Jul 15;20(14):4045-9. doi: 10.1016/j.bmcl.2010.05.096. Epub 2010 May 27.

PMID:
20561787
37.

AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.

Grimshaw KM, Hunter LJ, Yap TA, Heaton SP, Walton MI, Woodhead SJ, Fazal L, Reule M, Davies TG, Seavers LC, Lock V, Lyons JF, Thompson NT, Workman P, Garrett MD.

Mol Cancer Ther. 2010 May;9(5):1100-10. doi: 10.1158/1535-7163.MCT-09-0986. Epub 2010 Apr 27.

38.

Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).

McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, Ruddle R, Henley A, de Haven Brandon A, Valenti M, Davies TG, Fazal L, Seavers L, Raynaud FI, Eccles SA, Aherne GW, Garrett MD, Collins I.

J Med Chem. 2010 Mar 11;53(5):2239-49. doi: 10.1021/jm901788j.

39.

The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.

Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, Boxall KJ, Aherne GW, Eccles SA, Raynaud FI, Williams DH, Reader JC, Collins I, Garrett MD.

Mol Cancer Ther. 2010 Jan;9(1):89-100. doi: 10.1158/1535-7163.MCT-09-0938. Epub 2010 Jan 6.

40.

Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.

Hilton S, Naud S, Caldwell JJ, Boxall K, Burns S, Anderson VE, Antoni L, Allen CE, Pearl LH, Oliver AW, Wynne Aherne G, Garrett MD, Collins I.

Bioorg Med Chem. 2010 Jan 15;18(2):707-18. doi: 10.1016/j.bmc.2009.11.058. Epub 2009 Dec 6. Erratum in: Bioorg Med Chem. 2010 Jun 15;18(12):4591.

PMID:
20022510
41.

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, Garrett MD, Thomas GV, Workman P, Kaye SB, de Bono JS.

Drug Discov Today. 2010 Feb;15(3-4):88-97. doi: 10.1016/j.drudis.2009.11.006. Epub 2009 Dec 2. Review.

PMID:
19961955
42.

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P.

Cancer J. 2009 Sep-Oct;15(5):406-20. doi: 10.1097/PPO.0b013e3181bd0445. Review.

PMID:
19826361
43.

Identification of inhibitors of checkpoint kinase 1 through template screening.

Matthews TP, Klair S, Burns S, Boxall K, Cherry M, Fisher M, Westwood IM, Walton MI, McHardy T, Cheung KM, Van Montfort R, Williams D, Aherne GW, Garrett MD, Reader J, Collins I.

J Med Chem. 2009 Aug 13;52(15):4810-9. doi: 10.1021/jm900314j.

PMID:
19572549
44.

Structure and ultrafast dynamics of white-light-emitting CdSe nanocrystals.

Bowers MJ 2nd, McBride JR, Garrett MD, Sammons JA, Dukes AD 3rd, Schreuder MA, Watt TL, Lupini AR, Pennycook SJ, Rosenthal SJ.

J Am Chem Soc. 2009 Apr 29;131(16):5730-1. doi: 10.1021/ja900529h.

PMID:
19341271
45.

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.

Knight JF, Shepherd CJ, Rizzo S, Brewer D, Jhavar S, Dodson AR, Cooper CS, Eeles R, Falconer A, Kovacs G, Garrett MD, Norman AR, Shipley J, Hudson DL.

Br J Cancer. 2008 Dec 2;99(11):1849-58. doi: 10.1038/sj.bjc.6604774. Epub 2008 Nov 11.

46.

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.

Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P.

Curr Opin Pharmacol. 2008 Aug;8(4):393-412. doi: 10.1016/j.coph.2008.08.004. Epub 2008 Aug 27. Review.

PMID:
18721898
47.

Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by Src family kinases.

Martin NG, McAndrew PC, Eve PD, Garrett MD.

FEBS J. 2008 Jun;275(12):3099-109. doi: 10.1111/j.1742-4658.2008.06463.x. Epub 2008 May 8.

48.

Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.

Caldwell JJ, Davies TG, Donald A, McHardy T, Rowlands MG, Aherne GW, Hunter LK, Taylor K, Ruddle R, Raynaud FI, Verdonk M, Workman P, Garrett MD, Collins I.

J Med Chem. 2008 Apr 10;51(7):2147-57. doi: 10.1021/jm701437d. Epub 2008 Mar 18.

PMID:
18345609
49.

Effects of surface passivation on the exciton dynamics of CdSe nanocrystals as observed by ultrafast fluorescence upconversion spectroscopy.

Kippeny TC, Bowers MJ, Dukes AD 3rd, McBride JR, Orndorff RL, Garrett MD, Rosenthal SJ.

J Chem Phys. 2008 Feb 28;128(8):084713. doi: 10.1063/1.2834692.

PMID:
18315078
50.

The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.

Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD, Workman P.

Cell Cycle. 2007 Dec 15;6(24):3114-31. Epub 2007 Oct 5.

PMID:
18075315

Supplemental Content

Loading ...
Support Center